Article Information
History
- July 5, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Lorenzo Falchi1,2,#,
- Jahan Rahman3,4,#,
- Lauren Melendez3,
- Monifa Douglas1,
- Walter Ramos Amador1,
- Paul Hamlin1,2,
- Anita Kumar1,2,
- Daniela Hoehn5,
- Ya-Hui Lin3,
- Qi Gao6,
- Mikhail Roshal6,
- Mark D. Ewalt6,7,
- Ahmet Dogan6,
- Benjamin Greenbaum4,
- Gilles A. Salles1,2 and
- Santosha A. Vardhana1,2,3,*
- 1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
- 2Weill Cornell Medical College, New York, NY, USA
- 3Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
- 4Department of Epidemiology and Biostatistics, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, NY
- 5Genmab, Princeton, NJ
- 6Hematopathology service, Department of Pathology and Laboratory Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
- 7Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
- ↵*Corresponding authors: Lorenzo Falchi, Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 530 E 74th St, New York, NY 10021; Email: falchil{at}mskcc.org; tel. +1646-608-3705; Santosha A. Vardhana; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 417 E 68th St, New York, NY, 10065; vardhans{at}mskcc.org; tel. +1646-888-3285;
Posted July 05, 2024.
Intratumoral T-cell composition predicts epcoritamab-based treatment efficacy in B-cell non-Hodgkin lymphomas
